Transcript
04/11/2023 amr badreldin hamdy MD 1
Asthma Control
Clinical Pearls
04/11/2023 3
Amr Badreldin Hamdy, MD FCCP
Prof of Pulmonary Medicine
Banha University, EGYPTPulmonary Consultant
NEW CAPITAL MEDICAL CENTRE, ABU DHABI
Amr Badreldin Hamdy MD FCCP
Is There A Cure For Asthma?
Asthma cannot be cured, but it can be Controlled
“We should expect nothing less”!
In lay usage, “control” conveys the sense of being reined in or kept within certain boundaries.
The patient’s level of asthma control represents the extent to which the clinical manifestations of asthma have been removed or reduced by treatment.
The goals of asthma treatment are relating not only to the control of patient’s current symptoms, but also to the prevention of future adverse outcomes, such as exacerbations, a rapid decline in lung function and side-effects of treatment.
The assessment of asthma control falls into two broad categories: assessment of the current level of clinical control and assessment of future risk to the patient.
Asthma is a chronic inflammatory disorderof the airways.
This causes an increase in airway hyper-responsiveness leading to
o Wheezingo Breathlessnesso Chest tightnesso Coughing
GINA, 2002
04/11/2023 Amr Badreldin Hamdy MD FCCP 10
Amr Badreldin Hamdy MD FCCP
Asthma is one of the commonest chronic diseases worldwide and is increasing in children and probably also in adults.
04/11/2023 Amr Badreldin Hamdy MD FCCP 12
Burden of Asthma
The WHO has reported the annual costs of BA exceed those of TB and HIV combined due to poor asthma control and disease management.
Burden of Asthma-cont’d
The evaluation of asthma costs considers both direct costs (medication and treatment) and indirect costs (loss of school or working days and decrease in productivity).
04/11/2023 Amr Badreldin Hamdy MD FCCP 13
Asthma: limits daily-life activities
0
20
40
% o
f pa
tien
ts
60
Social activities
Career Choice
Housekeeping
Lifestyle
Normal Physical Activity
SleepingSports
Asia Pacific Europe US
Rabe et al. 2000; Fulbrigge et al. 2002; Lai et al. 2002
Amr Badreldin Hamdy MD FCCP
While it is a worldwide problem, the prevalence of the condition seems to be higher in affluent than non-affluent populations.
Amr Badreldin Hamdy MD FCCP
Under-diagnosis and under-treatment are major contributors to asthma morbidity and mortality.
Long term preventive treatment is the cornerstone of good asthma control.
Amr Badreldin Hamdy MD FCCP
Putting primary emphasis on controlling bronchial spasm rather than chronic airway inflammation looks like “putting the cart before the horse”.
Amr Badreldin Hamdy MD FCCP
Even following administration of one of the many forms of asthma treatment, up to 40% of adults remain symptomatic, and up to 5% of cases are difficult to manage despite multiple forms of treatment.
Amr Badreldin Hamdy MD FCCP
What Are Benefits Of Long Term Preventive Treatment
Of Asthma?
Achieving asthma control is the focus of all recently developed asthma treatment guidelines.
Amr Badreldin Hamdy MD FCCP
The goal is effective control of asthma, which strives to ensure that the asthmatic is able to lead a normal and physically active life.
Current clinical control is assessed by direct observation of the patient’s current or recent clinical status on treatment.
Amr Badreldin Hamdy MD FCCP
Remember!
One must always consider that the goal of total control of asthma must be balanced against the cost and potential adverse effects of asthma control.
The assessment of asthma control has two components: current clinical control (including symptoms, reliever use and simple “bedside” measures of lung function) and future risk of adverse outcomes (e.g. exacerbations, rapid decline in lung function, and side effects).
04/11/2023 Amr Badreldin Hamdy MD FCCP 25
What is asthma control?As defined by the Global Initiative for Asthma (GINA), 2007
oMinimal to no daytime asthma symptomsoNo limitations on activitiesoNo nocturnal symptoms or awakeningsoMinimal to no need for reliever or rescue
therapyoNormal lung function (FEV1 or PEF)oNo exacerbations
www.ginasthma.org
Exacerbations, by definition and clinical practice, are identified by a change from and return to previous status, i.e. by their time trend.
Exacerbations are events that are more common in poorly controlled asthma but may occur at any level of clinical asthma control.
What are the Key elements of an Asthma Program?
Amr Badreldin Hamdy MD FCCP
oEducation-motivation.oSelf assessment management.oEnvironmental management.oPharmacological management.
Amr Badreldin Hamdy MD FCCP
In the assessment of asthma control, there are several important activities that should be accomplished during the periodic visit for asthma:
Amr Badreldin Hamdy MD FCCP
1. Assessment of psychosocial status.
2. Assessment of adherence-compliance.
3. Assessment of medication use and its side effects.
Amr Badreldin Hamdy MD FCCP
4. Assessment of asthma triggers.
5. Review of written asthma action plan (as appropriate).
6. Confirmation of asthma diagnosis.
Amr Badreldin Hamdy MD FCCP
A common misconception is that asthma severity is considered “static”; namely, that once a patient is classified with a given severity level, it remains constant.
Asthma symptoms are a dynamic and often a changing parameter.
Amr Badreldin Hamdy MD FCCP
Asthma control can be expected to change over time. It should be assessed at every clinical encounter for asthma, and management decisions should be based on the level of asthma control.
Amr Badreldin Hamdy MD FCCP
If a patient has been stable on an asthma treatment program for a period of time, consideration should be given to try “stepping down” therapy to a less intense level of treatment plan.
Barriers of Effective Treatment
Amr Badreldin Hamdy MD FCCP
oFailure to agree to set a common goal with the patients.
oPatient resistance/objection to inhalation therapy.
oPoor inhalation technique.oSteroid phobia.oWorry about excessive cost.
04/11/2023 Amr Badreldin Hamdy MD FCCP 39
Key Goals in Patient Education
With the help of the health-care team, patients can learn to do the following:
o Avoid risk factors.o Understand the difference between “reliever” and
“controller” medications.o Monitor status using symptoms or PEFRo Recognize signs that asthma is worsening and take
action.
Aims of asthma management, which if achieved,indicate overall asthma control
oMinimal (ideally no) symptomsoMinimal (infrequent) exacerbationsoNo emergency visitsoMinimal (ideally no)PRN ß2-agonist useoNo activity restriction, including exerciseoPEF circadian variation less than 20%o (Near) normal PEFoMinimal (or no) adverse effects from medicines
GINA, 2002
Patients currently achieving control
Not Well-Controlled
Well-ControlledOnly 5% of patientsachieve asthma control
Rabe et al. Eur Respir J, 2000
04/11/2023 42
CAUSES OF NONRESPONSIVE ASTHMA
Amr Badreldin Hamdy MD FCCP
04/11/2023 43
1. Wrong diagnosis o COPDo Bronchiectasis, Cystic fibrosis,o Inhaled FBo Recurrent aspiration.o Obliterative bronchitis.o Tumors involving the central airway.o Tracheobronchomalacia.o Vocal cord dysfunction.
Amr Badreldin Hamdy MD FCCP
04/11/2023 44
2. Poor Adherence To Therapy
o Patient related.o Drug related.
Amr Badreldin Hamdy MD FCCP
04/11/2023 45
3. Unidentified Exacerbation Factorso Unidentified allergieso Occupational exposureo GERDo Systemic diseases (thyrotoxicosis,
carcinoid syndrome, Churg-Strauss Syndrome)
o Drugs (Beta-blockers, ACE-inhibitors)o Rhinitis/sinusitis/sleep apneao Psychological factors
Amr Badreldin Hamdy MD FCCP
04/11/2023 46
4. Unstable Asthma
o Nocturnal asthmao Pre-menstrual asthmao Brittle asthma
Amr Badreldin Hamdy MD FCCP
04/11/2023 47
5. Corticosteroid Dependant/Resistant Asthma.
Amr Badreldin Hamdy MD FCCP
Asthma PhenotypesoIntermittent/Persistent
– Mild/Moderate/Severe
oAdult onset wheezing– Primary asthma and secondary causes– Tends to me more severe
oOccupational asthmaoNeutrophilic inflammation
The asthma phenotypes may alter the intensity of treatment required (severity) and, in turn, contribute to the patient’s level of asthma control.
04/11/2023 50Amr Badreldin Hamdy MD FCCP
04/11/2023 Amr Badreldin Hamdy MD FCCP 51
Do we really avoid the triggers?
04/11/2023 Amr Badreldin Hamdy MD FCCP 52
Can We Control His Asthma?
04/11/2023 Amr Badreldin Hamdy MD FCCP 53
How to Avoid Pollution?
04/11/2023 Amr Badreldin Hamdy MD FCCP 54
Pest Elimination
04/11/2023 Amr Badreldin Hamdy MD FCCP 55
Pollen Elimination
04/11/2023 Amr Badreldin Hamdy MD FCCP 56
Asthma and Exercise
04/11/2023 Amr Badreldin Hamdy MD FCCP 57
Asthma and Fumes, Odors and Strong Scents
04/11/2023 Amr Badreldin Hamdy MD FCCP 58
Adherence
04/11/2023 Amr Badreldin Hamdy MD FCCP 59
Adherence Definition
It is a the extent to which a person’s behavior-taking medication, following a diet, and/or executing lifestyle changes, corresponds with agreed recommendations from a health care provider.
Rand CS. AJ Cardiology; 1993,72.
04/11/2023 Amr Badreldin Hamdy MD FCCP 60
Adherence Incidence
In developed countries, adherence to long-term therapies in the general population is around 50% and is much lower in developing countries.
04/11/2023 Amr Badreldin Hamdy MD FCCP 61
Evidence shows that adherence rates for the regular taking of preventive therapies are as low as 28% in developed countries.
Reid D et al., Respirology, 2000,5.
04/11/2023 Amr Badreldin Hamdy MD FCCP 62
Rates of non-adherence among patients with asthma range from 30% to 70%, whether adherence is measured as percentage of prescribed medication taken, serum theophylline levels, days of medication adherence, or percentage of patients who failed to reach a clinically estimated adherence minimum.Bender B et al, Ann Allergy, Asthma, & Immunology, 1997,79.
04/11/2023 Amr Badreldin Hamdy MD FCCP 63
Types of Non-compliance
04/11/2023 Amr Badreldin Hamdy MD FCCP 64
oReceiving a prescription but not filling it.o Taking an incorrect dose. o Taking medication at the wrong times.o Increasing or decreasing the frequency
of doses.o Stopping the treatment too soon.oNon-participation in clinic visits.o Failure to follow doctor’s instructions.
04/11/2023 Amr Badreldin Hamdy MD FCCP 65
o“Drug holidays”, which means the patient stops the therapy for a while and then restarts the therapy.
o“White-coat compliance”, which means patients are compliant to the medication regimen around the time of clinic appointments.
04/11/2023 Amr Badreldin Hamdy MD FCCP 66
Asthma Compliance Score
04/11/2023 Amr Badreldin Hamdy MD FCCP 67
Categories of Factors Identified From the Literature Review
04/11/2023 Amr Badreldin Hamdy MD FCCP 68
(1) Patient –centered FactorsoDemographic factors: age, ethnicity,
gender, education, marriage status.oPsychosocial factors: beliefs,
motivation, attitude.oPatient-prescriber relationship.oHealth literacy.oPatient knowledge.
04/11/2023 Amr Badreldin Hamdy MD FCCP 69
(2) Therapy-related FactorsoRoute of administration.o Treatment complexity.oMedication side effects.oDuration of the treatment period.oDegree of behavioral change required.o Taste of the medication.oRequirements for drug storage.
04/11/2023 Amr Badreldin Hamdy MD FCCP 70
(3) Healthcare System Factors
oLack of accessibility.oLong waiting time.oDifficulty in getting prescriptions
filled.oUnhappy clinic visits.
04/11/2023 Amr Badreldin Hamdy MD FCCP 71
(4) Social and Economic Factors
o Inability to take time off work.oCost and income.oSocial support.
04/11/2023 Amr Badreldin Hamdy MD FCCP 72
(5) Disease Factors
oDisease symptoms.oSeverity of the disease.
04/11/2023 Amr Badreldin Hamdy MD FCCP 73
How to Recognize Asthma Deterioration?
o Increasing frequency of severity of symptoms, especially waking at night.
o Increasing use of reliever medication.o Failure of medication to completely
relieve symptoms.o Falling peak flow and /or increasing peak
flow variability.
04/11/2023 Amr Badreldin Hamdy MD FCCP 74
continuedoPhysical difficulties.oTobacco smoking or alcohol intake.oForgetfulness.oHistory of good compliance.
How to Deal with a Non-responding Patient?
Amr Badreldin Hamdy MD FCCP
If a patient with asthma is not responding as we think they should, it’s time to “think new thoughts” and see if we are missing something that is undermining our treatment plan.
Incorrect inhaler choice or poor technique
o There is no clinical difference between inhaler devices when used correctly, but each type requires a different pattern of inhalation for optimal drug delivery to the lungs
o Problems with inhaler technique are common in clinical practice & can lead to poor asthma control
o Asthma control worsens as the number of mistakes in inhaler technique increases
o All patients should be trained in technique, and trainers should be competent with the inhalation technique
Inhaler choice and technique
o Take patient preference into account when choosing the inhaler device
o Simplify the regimen and do not mix inhaler device types
o The choice of steroid inhaler is most important because of the narrower therapeutic window
o Invest the time to train each patient in proper inhaler technique:
• Observe technique & let patient observe self (using video demonstrations)• Devices to check technique & maintain trained technique are available (eg, 2Tone
Trainer & Aerochamber Plus spacer for metered dose inhalers; In-Check Dial, Turbuhaler whistle, Novolizer for dry powder inhalers)
o Recheck inhaler technique on each revisitHaughney J et al. Respir Med. 2008;102:1681–93.
Evidence linking asthma & rhinitiso >50% of patients with asthma have rhinitiso Similar epidemiologyo Common triggerso Similar pattern of inflammation:
T helper type 2 cells, mast cells, eosinophilsoNasal challenge results in asthmatic
inflammation & vice versao Rhinitis predicts development of asthma
Thomas M. BMC Pulm Med. 2006;6:S4.
Unintentional versus intentional nonadherence
Perceptual–Practical Model of Adherence(can’t take, won’t take)
UNINTENTIONAL
nonadherence
INTENTIONAL
nonadherence
Capacity & resources
Practical barriers
Motivational
Beliefs/preferences
Perceptual barriers
Horne R et al. 2005. National Co-ordinating Centre for NHS Service Delivery and Organisation R&D, London.
Intentional non adherence derives from the balance between the patient’s beliefs about the personal necessity of taking a given medication relative to any concerns about taking it
Degree of Asthma Control
The terms severity and control should not be regarded as synonymous, as patients with severe asthma may be well controlled on high doses of treatment and patients with mild asthma may be currently poorly controlled, e.g. owing to poor compliance.
Severity is described by the intensity of the treatment required to achieve good control.
The probability of a patient becoming well controlled is independent of their baseline severity (their baseline dose of ICS).
The level of asthma control results from the interaction of the underlying phenotype, the environment (genetic and external) and the response to treatment.
Amr Badreldin Hamdy MD FCCP
Poor Controlled Asthma
oThe occurrence of prior near fatal episode.
oRecent hospitalization.oRecent emergency room visit.oNight time symptoms.oLimitation of daily activities.
Amr Badreldin Hamdy MD FCCP
Need for inhaled beta2-agonists several times per day or at night.
FEV1 or PEFR less than 60% predicted.
Amr Badreldin Hamdy MD FCCP
Well Controlled Asthma
oAsthma symptoms are twice a week or less.
oRescue bronchodilator medication is used twice a week or less.
oThere is no nocturnal or early morning awakening.
oThere are no limitations of work, school, or exercise.
Amr Badreldin Hamdy MD FCCP
oThe patient and physician consider their asthma well controlled.
oThe patient’s PEF or FEV1 is normal or his/her personal best.
Amr Badreldin Hamdy MD FCCP
Complete (Total) Controlled Asthma
oNo asthma symptoms.oNo rescue bronchodilator use.oNo night or early morning awakening.oNo limitations on exercise, work, school.oComplete control of asthma by patient
assessment and normal best PEF or FEV1.
Patients Physicians
Healthcare system
TOTAL CONTROL
Raising expectations…
Researchers
Drugs Used for Control
In 1995, the GINA guidelines introduced the concept of the medication required to maintain control.
Amr Badreldin Hamdy MD FCCP
Preventers
These have anti-inflammatory actions (ICS, Cromones).
Amr Badreldin Hamdy MD FCCP
Controllers
Drugs which have a sustained bronchial dilatation action, but unproven anti-inflammatory action ( LABA, SR xanthines, Leukotriene receptor antagonists).
Amr Badreldin Hamdy MD FCCP
Relievers
For acute relief from symptoms.
04/11/2023 Amr Badreldin Hamdy MD FCCP 97
Referenceso Hess DR: Aerosol delivery devices in the
treatment of asthma. Respiratory Care, 2008; 53(6):699.
o Castro M & Kraft M: Clinical Asthma. Mosby El Servier, 2008.
o Bush RK & Georgitis J.W.: Handbook of Asthma and Allergic Rhinitis. Blackwell Publ. Ltd., 1977.
04/11/2023 Amr Badreldin Hamdy MD FCCP 98
o Lavorini F. & Corbetta L.: Achieving Asthma Control: The Key Role of Inhalers. Breathe, 2008; 5(2):121.
o Bateman ED et al.: Achieving Guideline-based Asthma control: Does the Patient Benefit?. Eur Respir J 2002; 20:588.
o Soubra S & Guntupalli KK: Acute Respiratory Failure In Asthma. Indian J Crit Care Med 2005; 9(4):225.
04/11/2023 Amr Badreldin Hamdy MD FCCP 99
o Kankaanranta H et al: Add-on Therapy Options in Asthma not Adequately Controlled by ICS: A comprehensive Review. Respiratory Research 2004; 5:17.
o WHO: adherence to Long-term therapies. Evidence for Action 2003.
o Kristin Casler: Asthma. Questions you have…Answers you need. People’s Medical Society 1998.
04/11/2023 Amr Badreldin Hamdy MD FCCP 100
THANK YOU
top related